Machine learning unveils immune-related signature in multicenter glioma studies

作者全名：Yang, Sha; Wang, Xiang; Huan, Renzheng; Deng, Mei; Kong, Zhuo; Xiong, Yunbiao; Luo, Tao; Jin, Zheng; Liu, Jian; Chu, Liangzhao; Han, Guoqiang; Zhang, Jiqin; Tan, Ying

作者地址：[Yang, Sha; Liu, Jian] Guizhou Univ, Med Coll, Guiyang 550025, Guizhou, Peoples R China; [Wang, Xiang; Chu, Liangzhao] Guizhou Med Univ, Affiliated Hosp, Dept Neurosurg, Guiyang 550004, Peoples R China; [Huan, Renzheng] Chongqing Med Univ, Affiliated Hosp 2, Dept Neurosurg, Chongqing 400010, Peoples R China; [Deng, Mei; Kong, Zhuo; Xiong, Yunbiao; Luo, Tao; Jin, Zheng; Liu, Jian; Han, Guoqiang; Tan, Ying] Guizhou Prov Peoples Hosp, Dept Neurosurg, Guiyang, Peoples R China; [Zhang, Jiqin] Guizhou Prov Peoples Hosp, Dept Anesthesiol, Guiyang, Peoples R China

通信作者：Han, GQ; Tan, Y (通讯作者)，Guizhou Prov Peoples Hosp, Dept Neurosurg, Guiyang, Peoples R China.; Zhang, JQ (通讯作者)，Guizhou Prov Peoples Hosp, Dept Anesthesiol, Guiyang, Peoples R China.

来源：ISCIENCE

ESI学科分类：　

WOS号：WOS:001211015700001

JCR分区：Q1

影响因子：4.6

年份：2024

卷号：27

期号：4

开始页：　

结束页：　

文献类型：Article

关键词：　

摘要：In glioma molecular subtyping, existing biomarkers are limited, prompting the development of new ones. We present a multicenter study -derived consensus immune -related and prognostic gene signature (CIPS) using an optimal risk score model and 101 algorithms. CIPS, an independent risk factor, showed stable and powerful predictive performance for overall and progression -free survival, surpassing traditional clinical variables. The risk score correlated significantly with the immune microenvironment, indicating potential sensitivity to immunotherapy. High -risk groups exhibited distinct chemotherapy drug sensitivity. Seven signature genes, including IGFBP2 and TNFRSF12A, were validated by qRT-PCR, with higher expression in tumors and prognostic relevance. TNFRSF12A, upregulated in GBM, demonstrated inhibitory effects on glioma cell proliferation, migration, and invasion. CIPS emerges as a robust tool for enhancing individual glioma patient outcomes, while IGFBP2 and TNFRSF12A pose as promising tumor markers and therapeutic targets.

基金机构：National Natural Science Foundation of China [82360482, 82260533, 82360376, 81960454, 81960344]; Guizhou Provincial Science and Technology Projects [[2020] 1Z066]

基金资助正文：We sincerely thank the consenting patients, enabling this research. Recognition goes to the Institutional Research Ethics Committee of Guizhou Provincial People's Hospital for approval [Approval Number: (2019)122], emphasizing their dedication to research ethics. Gratitude extends to public database creators and maintainers, notably UCSC Xena (https://tcga.xenahubs.net) , CGGA website (http://www.cgga.org.cn/) , and GLIOVIS database (http://GLIOVIS.bioinfo.cnio.es/) . These databases enriched our study comprehensively. We acknowledge financial support from the National Natural Science Foundation of China (Grants: 82360482, 82260533, 82360376, 81960454, 81960344) and Guizhou Provincial Science and Technology Projects (Grant: [2020] 1Z066) , vital for our research completion.